bioRxivSystems BiologyPreprint
PROFILING OF Y1 CELLS TREATED WITH FGF-2 REVEALS PARALLELS WITH ONCOGENE-INDUCED SENESCENCE
Peder J. LundiD, Mariana de Camargo LopesiD, Simone SidoliiD, Mariel CoradiniD, Francisca N. de Luna VitorinoiD, Júlia Pinheiro Chagas da CunhaiD, Benjamin Aaron GarciaiD
- Citations
- 0
Abstract
Paradoxically, oncogenes that drive cell cycle progression may also trigger pathways leading to senescence, thereby inhibiting the growth of tumorigenic cells. Along these lines, Y1 cells, which carry an amplification of Ras, become senescent after treatment with the mitogen FGF-2. To understand how FGF-2 promotes senescence, we profiled the epigenome, transcriptome, proteome, and phospho-proteome of Y1 cells stimulated with FGF-2. FGF-2 caused delayed acetylation of histone H4 and higher levels of H3K27me3. Sequencing analysis revealed decreased expression of cell cycle-related genes with concomitant loss of H3K27ac. In contrast, FGF-2 promoted the expression of p21, various cytokines, and MAPK-related genes. Nuclear envelope proteins, particularly lamin B1, displayed increased phosphorylation in response to FGF-2. Proteome analysis suggested alterations in cellular metabolism, as evident by modulated expression of enzymes involved in purine biosynthesis, tRNA aminoacylation, and the TCA cycle. Altogether, the response of Y1 cells to FGF-2 is consistent with oncogene-induced senescence. We propose that Y1 cells enter senescence due to deficient cyclin expression and high levels of p21, which may stem from DNA damage or TGFb signaling.
- organism: mouse
- assay: proteomics
- assay: DNA methylation
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- TRAIL pathway suppression of cancer cell growth and immune cell-mediated tumor cell-killing in a senescent fibroblast-constructed tumor microenvironment
S. Zhang, K. E. Huntington, … W. S. El-Deiry·bioRxiv·Nov 30, 2023
- Early growth response 2 (EGR2) is a novel regulator of the senescence program
E. J. Tyler, A. Gutierrez Del Arroyo, … C. L. Bishop·bioRxiv·Sep 30, 2020
- A comprehensive temporal proteome and phosphoproteome dataset of Y1 adrenocortical cells under FGF2 stimulation and SOS inhibition
Fabio Montoni, Toshiki Hanada, … Yayoi Natsume‐Kitatani·bioRxiv·Oct 20, 2026
- Fibroblast Growth Factor 2 lethally sensitizes cancer cells to stress-targeted therapeutic inhibitors
M. H. Dias, C. S. Fonseca, … H. A. Armelin·Molecular OncologyPeer-reviewed·Dec 3, 2018
- A small molecule that promotes cellular senescence prevents fibrogenesis and tumorigenesis in vitro
B.-S. Youn, M. K. Meang, … H.-S. Kim·bioRxiv·Jun 1, 2021
- UHRF1 Overexpression Generates Distinct Senescent States with Different Tp53 Dependencies
Elena Magnani, Charlene Chen, … Kirsten C. Sadler·EMBO ReportsPeer-reviewed·Sep 28, 2026